Kane Biotech Q2 2024 Earnings Report C$0.10 0.00 (0.00%) (As of 12/20/2024 05:17 PM ET) Earnings History Kane Biotech EPS ResultsActual EPS-C$0.01Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AKane Biotech Revenue ResultsActual Revenue$0.62 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AKane Biotech Announcement DetailsQuarterQ2 2024Date8/29/2024TimeN/AConference Call ResourcesKNE Earnings History URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Kane Biotech Earnings HeadlinesKane Biotech Announces Change in US Distribution Partner for revyve(TM) Antimicrobial Wound GelNovember 28, 2024 | stockhouse.comKane Biotech Announces Health Canada Approval of revyve™ Antimicrobial Wound GelNovember 14, 2024 | markets.businessinsider.com$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being carried out by the Fed that has nothing to do with lowering or raising interest rates... but could soon have an enormous impact on your wealth.December 22, 2024 | Stansberry Research (Ad)Kane Biotech Provides Investor Update Following FB Dermatology Acquisition AnnouncementNovember 14, 2024 | markets.businessinsider.comKane Biotech Announces Agreement to Acquire FB DermatologyNovember 12, 2024 | markets.businessinsider.comKane Biotech Announces Donation of revyve™ Antimicrobial Wound Gel to UkraineOctober 23, 2024 | markets.businessinsider.comSee More Kane Biotech Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Kane Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kane Biotech and other key companies, straight to your email. Email Address About Kane BiotechKane Biotech (CVE:KNE), a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand. The company is also developing coactiv+ Antimicrobial Surgical Hydrogel for use in surgical/acute wounds; coactiv+ Antimicrobial Wound Rinse for use in acute and chronic wounds; coactiv+ Antimicrobial Wound Gel Spray for use in acute, chronic wounds, and first and second degree burns; and DispersinB Hydrogel for prosthetic joint infection. Kane Biotech Inc. was incorporated in 2001 and is based in Winnipeg, Canada.View Kane Biotech ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
